Anti-muc16 antibodies and uses thereof

By developing antibodies and antigen-binding fragments that specifically bind to the extracellular portion of MUC16, the problem of difficulty in identifying the non-shedding region of MUC16 in ovarian cancer cells in existing technologies has been solved, thus improving the diagnosis and treatment of ovarian cancer.

CN115368460BActive Publication Date: 2026-06-12MEMORIAL SLOAN KETTERING CANCER CENT
View PDF 76 Cites 0 Cited by

Patent Information

Application Number
CN202210174122.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2015-03-17
Filing Date
2016-03-16
Publication Date
2026-06-12
Estimated Expiration
2036-03-16

AI Technical Summary

Technical Problem

Existing antibodies have difficulty effectively binding to the non-shedding region of MUC16 overexpressed on the surface of ovarian cancer cells, limiting the effectiveness of diagnosis and treatment.

Method used

A series of antibodies and antigen-binding fragments have been developed that specifically bind to the extracellular portion of the MUC16 protein, especially glycosylation sites such as Asn1806 or Asn1800, for the preparation of fusion proteins, conjugates, and chimeric antigen receptors for the treatment of ovarian cancer.

Benefits of technology

These antibodies and antigen-binding fragments can specifically recognize the extracellular portion of MUC16, enhancing the diagnosis and treatment of ovarian cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_5
    Figure SMS_5
  • Figure SMS_6
    Figure SMS_6
  • Figure SMS_7
    Figure SMS_7
Patent Text Reader

Abstract

Provided herein are compositions, methods, and uses relating to antibodies that immunospecifically bind to glycosylated forms of MUC16, a tethered mucin. Also provided herein are uses and methods for managing, treating, or preventing a disease, e.g., cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Process for preparing acetylaminobenzenes

    EP0001994A1

  • Device in powder inhalators

    EP0237507A1

  • Recombinant antibodies and methods for their production

    EP0239400A2

  • A method for reducing the immunogenicity of antibody variable domains

    EP0519596A1

  • Resurfacing of rodent antibodies

    EP0592106A1